ArticleJournal of global antimicrobial resistance2022
Genotyping and macrolide-resistant mutation of Bordetella pertussis in East and South-East Asia.
Article in Journal of global antimicrobial resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Co-infection with macrolide-resistant and macrolide-susceptibleASM case reports · 2026Article
- Pertussis resurgence after the COVID-19 pandemic in four Western Pacific Countries and the USA, highlighting the 2025 outbreak in Japan.Scientific reports · 2026Article
- Epidemiological and clinical characteristics of macrolide-resistant Bordetella pertussis in southern China: an 8-year retrospective study.BMC infectious diseases · 2026Article
- Molecular Analysis of Emerging MT27 Macrolide-Resistant Bordetella pertussis, Kobe, Japan, 2025.Emerging infectious diseases · 2026Article
- Revisiting Whooping Cough: Global Drivers and Implications of Pertussis Resurgence in the Acellular Vaccine Era.Vaccines · 2025Review
- Absence of Macrolide-Resistant Mutations inOpen forum infectious diseases · 2025Article
- Macrolide-ResistantMicroorganisms · 2025Article
- Pertussis in the Post-COVID-19 Era: Resurgence, Diagnosis, and Management.Infection & chemotherapy · 2025Review
- MASP1 modulation as a novel therapeutic target in severe pediatric pertussis: insights from a multi-omics approach.Infection and immunity · 2025Article
- DecipheringJournal of clinical microbiology · 2024Article
- Whole-genome comparison of two same-genotype macrolide-resistant Bordetella pertussis isolates collected in Japan.PloS one · 2024Article
- [Pertussis worldwide. Vaccinating children and adults].Medecine tropicale et sante internationale · 2023Article
- Review
- Molecular Evolution and Increasing Macrolide Resistance of Bordetella pertussis, Shanghai, China, 2016-2022.Emerging infectious diseases · 2023Article
- Severe problem of macrolides resistance to common pathogens in China.Frontiers in cellular and infection microbiology · 2023Review
- Macrolide Resistance inAntibiotics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 4 countries.
Funding
Abstract
objectivesMacrolide-resistant Bordetella pertussis (MRBP) has been emerging and prevailing in mainland China since 2011. In this study, we aimed to investigate the genotype and macrolide resistance of circulating B. pertussis in East and Southeast Asia using genetic analyses.
methodsA total of 302 DNA extracts from clinical specimens and isolates from 2010 to 2020 were analyzed: 145 from Vietnam, 76 from Cambodia, 48 from Taiwan, and 33 from Japan. Genotypes were determined by multilocus variable-number tandem-repeat analysis (MLVA). Macrolide-resistant A2047G mutation in B. pertussis 23S rRNA was investigated using the duplex Cycleave real-time polymerase chain reaction (PCR) assay. Whole-genome sequencing was performed on two MRBP isolates that were identified for the first time in Taiwan.
resultsOverall, 286 DNA extracts (95%) generated a complete MLVA genotype and 283 DNA extracts (94%) yielded a complete result for the A2047G mutation analysis. The A2047G mutation was detected in 18 DNA extracts: fourteen from Vietnam, one from Cambodia, two from Taiwan, and one from Japan. Most of them (78%) showed the genotypes MT104 and MT195, which have previously been reported in Chinese MRBP isolates. Further, the Taiwanese MRBP isolates were classified into the MT104 clade of Chinese MRBP isolates.
conclusionAfter MRBP emerged and spread in mainland China, it may have spread to East and Southeast Asia in the 2010s. Continued surveillance targeting the A2047G mutation of MRBP is needed to prevent further spread of this emerging pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.